Lineage Cell Therapeutics, Inc. Logo

Lineage Cell Therapeutics, Inc.

LCTX

(1.5)
Stock Price

0,56 USD

-53.05% ROA

-29.91% ROE

-6.78x PER

Market Cap.

164.023.818,00 USD

4.32% DER

0% Yield

-230.66% NPM

Lineage Cell Therapeutics, Inc. Stock Analysis

Lineage Cell Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Lineage Cell Therapeutics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (5%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (2.23x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

4 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

5 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

6 ROE

Negative ROE (-30.25%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

7 ROA

The stock's ROA (-41.08%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-1) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Lineage Cell Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Lineage Cell Therapeutics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Lineage Cell Therapeutics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Lineage Cell Therapeutics, Inc. Revenue
Year Revenue Growth
1992 100.000
1993 100.000 0%
1994 100.000 0%
1995 100.000 0%
1996 100.000 0%
1997 100.000 0%
1997 100.000 0%
1998 300.000 66.67%
1999 1.037.500 71.08%
2000 52.492 -1876.49%
2001 151.917 65.45%
2002 387.020 60.75%
2003 556.422 30.44%
2004 688.377 19.17%
2005 903.200 23.78%
2006 1.162.015 22.27%
2007 1.046.121 -11.08%
2008 1.503.792 30.43%
2009 1.925.168 21.89%
2010 3.680.300 47.69%
2011 4.354.762 15.49%
2012 1.692.869 -157.24%
2013 2.861.007 40.83%
2014 1.946.372 -46.99%
2015 2.534.000 23.19%
2016 2.252.000 -12.52%
2017 1.792.000 -25.67%
2018 1.416.000 -26.55%
2019 1.478.000 4.19%
2020 773.000 -91.2%
2021 3.896.000 80.16%
2022 14.703.000 73.5%
2023 4.984.000 -195%
2023 8.945.000 44.28%
2024 5.632.000 -58.82%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Lineage Cell Therapeutics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1992 0
1993 0 0%
1994 800.000 100%
1995 1.800.000 55.56%
1996 0 0%
1997 2.100.000 100%
1997 2.100.000 0%
1998 1.700.000 -23.53%
1999 4.900.521 65.31%
2000 3.362.841 -45.73%
2001 1.685.168 -99.56%
2002 1.103.490 -52.71%
2003 903.018 -22.2%
2004 1.123.261 19.61%
2005 1.525.686 26.38%
2006 1.422.257 -7.27%
2007 967.864 -46.95%
2008 1.706.214 43.27%
2009 2.968.987 42.53%
2010 7.892.024 62.38%
2011 13.699.691 42.39%
2012 18.116.688 24.38%
2013 26.609.423 31.92%
2014 37.532.624 29.1%
2015 42.604.000 11.9%
2016 36.106.000 -18%
2017 24.024.000 -50.29%
2018 20.955.000 -14.65%
2019 17.948.000 -16.75%
2020 12.317.000 -45.72%
2021 33.914.000 63.68%
2022 13.987.000 -142.47%
2023 14.964.000 6.53%
2023 15.575.000 3.92%
2024 11.472.000 -35.77%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Lineage Cell Therapeutics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 1.200.000 100%
1997 1.200.000 0%
1998 0 0%
1999 1.896.690 100%
2000 1.779.931 -6.56%
2001 1.961.342 9.25%
2002 1.318.159 -48.79%
2003 1.260.712 -4.56%
2004 1.484.372 15.07%
2005 1.395.925 -6.34%
2006 1.491.622 6.42%
2007 1.300.630 -14.68%
2008 2.620.210 50.36%
2009 2.476.447 -5.81%
2010 5.640.409 56.09%
2011 9.341.502 39.62%
2012 10.365.045 9.87%
2013 15.558.674 33.38%
2014 17.556.102 11.38%
2015 29.134.000 39.74%
2016 28.426.000 -2.49%
2017 19.922.000 -42.69%
2018 24.726.000 19.43%
2019 24.031.000 -2.89%
2020 15.571.000 -54.33%
2021 18.212.000 14.5%
2022 22.508.000 19.09%
2023 16.164.000 -39.25%
2023 17.302.000 6.58%
2024 17.452.000 0.86%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Lineage Cell Therapeutics, Inc. EBITDA
Year EBITDA Growth
1992 -800.000
1993 -1.400.000 42.86%
1994 -1.800.000 22.22%
1995 -2.700.000 33.33%
1996 -2.100.000 -28.57%
1997 -3.400.000 38.24%
1997 -3.400.000 0%
1998 -2.200.000 -54.55%
1999 -5.979.998 63.21%
2000 -5.180.078 -15.44%
2001 -3.313.332 -56.34%
2002 -1.548.532 -113.97%
2003 -1.917.610 19.25%
2004 -952.297 -101.37%
2005 -2.035.175 53.21%
2006 -1.769.710 -15%
2007 -1.239.299 -42.8%
2008 -2.813.405 55.95%
2009 -3.515.787 19.98%
2010 -6.712.583 47.62%
2011 -16.532.721 59.4%
2012 -24.993.821 33.85%
2013 -17.120.299 -45.99%
2014 -50.673.648 66.21%
2015 -63.169.000 19.78%
2016 -142.376.000 55.63%
2017 -53.970.000 -163.81%
2018 -32.191.000 -67.66%
2019 -54.301.000 40.72%
2020 -25.012.000 -117.1%
2021 -52.791.000 52.62%
2022 -19.824.000 -166.3%
2023 -25.876.000 23.39%
2023 -24.041.000 -7.63%
2024 -22.900.000 -4.98%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Lineage Cell Therapeutics, Inc. Gross Profit
Year Gross Profit Growth
1992 -300.000
1993 -500.000 40%
1994 100.000 600%
1995 100.000 0%
1996 100.000 0%
1997 100.000 0%
1997 100.000 0%
1998 300.000 66.67%
1999 1.097.040 72.65%
2000 127.950 -757.4%
2001 151.917 15.78%
2002 387.020 60.75%
2003 556.422 30.44%
2004 688.377 19.17%
2005 903.200 23.78%
2006 1.162.015 22.27%
2007 1.046.121 -11.08%
2008 1.503.792 30.43%
2009 1.925.168 21.89%
2010 3.680.300 47.69%
2011 4.354.762 15.49%
2012 1.258.598 -246%
2013 2.068.348 39.15%
2014 1.109.320 -86.45%
2015 1.427.000 22.26%
2016 1.894.000 24.66%
2017 1.624.000 -16.63%
2018 1.114.000 -45.78%
2019 1.066.000 -4.5%
2020 388.000 -174.74%
2021 2.470.000 84.29%
2022 13.975.000 82.33%
2023 4.308.000 -224.4%
2023 7.582.000 43.18%
2024 4.888.000 -55.11%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Lineage Cell Therapeutics, Inc. Net Profit
Year Net Profit Growth
1992 -700.000
1993 -1.200.000 41.67%
1994 -1.500.000 20%
1995 -2.400.000 37.5%
1996 -2.000.000 -20%
1997 -3.000.000 33.33%
1997 -3.000.000 0%
1998 -2.100.000 -42.86%
1999 -5.479.884 61.68%
2000 -4.925.024 -11.27%
2001 -3.658.825 -34.61%
2002 -2.844.932 -28.61%
2003 -1.742.074 -63.31%
2004 -3.085.324 43.54%
2005 -2.074.251 -48.74%
2006 -1.864.621 -11.24%
2007 -1.438.226 -29.65%
2008 -3.780.895 61.96%
2009 -5.143.909 26.5%
2010 -11.184.618 54.01%
2011 -16.515.500 32.28%
2012 -21.425.703 22.92%
2013 -43.882.835 51.18%
2014 -36.411.660 -20.52%
2015 -46.991.000 22.51%
2016 33.572.000 239.97%
2017 -19.976.000 268.06%
2018 -45.990.000 56.56%
2019 -11.827.000 -288.86%
2020 -20.685.000 42.82%
2021 -38.564.000 46.36%
2022 -26.353.000 -46.34%
2023 -28.440.000 7.34%
2023 -21.486.000 -32.37%
2024 -23.040.000 6.74%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Lineage Cell Therapeutics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1997 0 0%
1998 0 0%
1999 -1 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 -1 0%
2014 -1 0%
2015 -1 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Lineage Cell Therapeutics, Inc. Free Cashflow
Year Free Cashflow Growth
1992 -600.000
1993 -1.300.000 53.85%
1994 -1.600.000 18.75%
1995 -2.100.000 23.81%
1996 -2.100.000 0%
1997 -1.300.000 -61.54%
1997 -1.400.000 7.14%
1998 -2.100.000 33.33%
1999 -4.556.620 53.91%
2000 -4.890.432 6.83%
2001 -3.214.950 -52.12%
2002 -2.132.986 -50.73%
2003 -654.144 -226.07%
2004 -1.536.696 57.43%
2005 -1.414.148 -8.67%
2006 -1.272.883 -11.1%
2007 -1.246.453 -2.12%
2008 -2.464.117 49.42%
2009 -4.321.214 42.98%
2010 -8.168.655 47.1%
2011 -14.555.697 43.88%
2012 -20.080.328 27.51%
2013 -31.785.781 36.83%
2014 -39.337.297 19.2%
2015 -49.878.000 21.13%
2016 -44.852.000 -11.21%
2017 -31.843.000 -40.85%
2018 -34.169.000 6.81%
2019 -32.387.000 -5.5%
2020 -19.817.000 -63.43%
2021 -23.915.000 17.14%
2022 646.000 3802.01%
2023 -29.240.000 102.21%
2023 -5.176.000 -464.91%
2024 -5.226.000 0.96%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Lineage Cell Therapeutics, Inc. Operating Cashflow
Year Operating Cashflow Growth
1992 -600.000
1993 -1.300.000 53.85%
1994 -1.600.000 18.75%
1995 -2.000.000 20%
1996 -2.100.000 4.76%
1997 -1.300.000 -61.54%
1997 -1.300.000 0%
1998 -2.100.000 38.1%
1999 -4.394.901 52.22%
2000 -4.857.030 9.51%
2001 -3.209.834 -51.32%
2002 -2.129.155 -50.76%
2003 -654.144 -225.49%
2004 -1.536.696 57.43%
2005 -1.414.148 -8.67%
2006 -1.262.219 -12.04%
2007 -1.239.980 -1.79%
2008 -1.604.245 22.71%
2009 -4.259.938 62.34%
2010 -7.732.884 44.91%
2011 -13.593.916 43.12%
2012 -19.679.518 30.92%
2013 -29.508.613 33.31%
2014 -38.854.200 24.05%
2015 -44.544.000 12.77%
2016 -42.326.000 -5.24%
2017 -30.517.000 -38.7%
2018 -30.882.000 1.18%
2019 -31.947.000 3.33%
2020 -19.753.000 -61.73%
2021 -23.561.000 16.16%
2022 1.059.000 2324.83%
2023 -28.566.000 103.71%
2023 -5.037.000 -467.12%
2024 -5.176.000 2.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Lineage Cell Therapeutics, Inc. Capital Expenditure
Year Capital Expenditure Growth
1992 0
1993 0 0%
1994 0 0%
1995 100.000 100%
1996 0 0%
1997 0 0%
1997 100.000 100%
1998 0 0%
1999 161.719 100%
2000 33.402 -384.16%
2001 5.116 -552.89%
2002 3.831 -33.54%
2003 0 0%
2004 0 0%
2005 0 0%
2006 10.664 100%
2007 6.473 -64.75%
2008 859.872 99.25%
2009 61.276 -1303.28%
2010 435.771 85.94%
2011 961.781 54.69%
2012 400.810 -139.96%
2013 2.277.168 82.4%
2014 483.097 -371.37%
2015 5.334.000 90.94%
2016 2.526.000 -111.16%
2017 1.326.000 -90.5%
2018 3.287.000 59.66%
2019 440.000 -647.05%
2020 64.000 -587.5%
2021 354.000 81.92%
2022 413.000 14.29%
2023 674.000 38.72%
2023 139.000 -384.89%
2024 50.000 -178%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Lineage Cell Therapeutics, Inc. Equity
Year Equity Growth
1992 4.600.000
1993 3.400.000 -35.29%
1994 5.800.000 41.38%
1995 3.200.000 -81.25%
1996 2.800.000 -14.29%
1997 6.500.000 56.92%
1997 6.500.000 0%
1998 2.400.000 -170.83%
1999 5.083.132 52.79%
2000 1.317.735 -285.75%
2001 -99.094 1429.78%
2002 -1.171.146 91.54%
2003 -2.430.551 51.82%
2004 344.770 804.98%
2005 -196.581 275.38%
2006 -1.865.221 89.46%
2007 -3.046.389 38.77%
2008 -4.346.814 29.92%
2009 11.046.989 139.35%
2010 49.425.657 77.65%
2011 41.458.181 -19.22%
2012 24.294.373 -70.65%
2013 42.262.321 42.52%
2014 62.722.765 32.62%
2015 76.447.000 17.95%
2016 130.508.000 41.42%
2017 164.263.000 20.55%
2018 92.246.000 -78.07%
2019 111.247.000 17.08%
2020 95.127.000 -16.95%
2021 90.898.000 -4.65%
2022 71.936.000 -26.36%
2023 62.023.000 -15.98%
2023 66.660.000 6.96%
2024 66.875.000 0.32%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Lineage Cell Therapeutics, Inc. Assets
Year Assets Growth
1992 4.800.000
1993 3.500.000 -37.14%
1994 5.900.000 40.68%
1995 3.600.000 -63.89%
1996 3.000.000 -20%
1997 8.300.000 63.86%
1997 8.300.000 0%
1998 2.800.000 -196.43%
1999 5.678.644 50.69%
2000 1.677.484 -238.52%
2001 1.941.375 13.59%
2002 1.496.081 -29.76%
2003 1.071.545 -39.62%
2004 1.521.589 29.58%
2005 1.958.784 22.32%
2006 650.507 -201.12%
2007 175.102 -271.5%
2008 1.035.457 83.09%
2009 13.433.071 92.29%
2010 53.272.659 74.78%
2011 45.829.695 -16.24%
2012 29.748.593 -54.06%
2013 57.729.750 48.47%
2014 74.900.906 22.93%
2015 94.660.000 20.87%
2016 142.572.000 33.61%
2017 173.241.000 17.7%
2018 101.660.000 -70.41%
2019 125.478.000 18.98%
2020 107.949.000 -16.24%
2021 174.545.000 38.15%
2022 123.664.000 -41.14%
2023 101.019.000 -22.42%
2023 106.153.000 4.84%
2024 102.802.000 -3.26%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Lineage Cell Therapeutics, Inc. Liabilities
Year Liabilities Growth
1992 200.000
1993 100.000 -100%
1994 100.000 0%
1995 400.000 75%
1996 200.000 -100%
1997 1.800.000 88.89%
1997 1.800.000 0%
1998 400.000 -350%
1999 595.512 32.83%
2000 359.749 -65.54%
2001 2.040.469 82.37%
2002 2.667.227 23.5%
2003 3.502.096 23.84%
2004 1.176.819 -197.59%
2005 2.155.365 45.4%
2006 2.515.728 14.32%
2007 3.221.491 21.91%
2008 5.382.271 40.15%
2009 2.386.082 -125.57%
2010 3.847.002 37.98%
2011 4.371.514 12%
2012 5.454.220 19.85%
2013 15.467.429 64.74%
2014 12.178.141 -27.01%
2015 18.213.000 33.13%
2016 12.064.000 -50.97%
2017 8.978.000 -34.37%
2018 9.414.000 4.63%
2019 14.231.000 33.85%
2020 12.822.000 -10.99%
2021 83.647.000 84.67%
2022 51.728.000 -61.71%
2023 38.996.000 -32.65%
2023 39.493.000 1.26%
2024 35.927.000 -9.93%

Lineage Cell Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.03
Net Income per Share
-0.13
Price to Earning Ratio
-6.78x
Price To Sales Ratio
26.52x
POCF Ratio
-7.45
PFCF Ratio
-7.34
Price to Book Ratio
2.4
EV to Sales
22.2
EV Over EBITDA
-5.52
EV to Operating CashFlow
-6.24
EV to FreeCashFlow
-6.15
Earnings Yield
-0.15
FreeCashFlow Yield
-0.14
Market Cap
0,16 Bil.
Enterprise Value
0,14 Bil.
Graham Number
1.02
Graham NetNet
0.01

Income Statement Metrics

Net Income per Share
-0.13
Income Quality
0.91
ROE
-0.36
Return On Assets
-0.21
Return On Capital Employed
-0.27
Net Income per EBT
1
EBT Per Ebit
0.88
Ebit per Revenue
-2.61
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
2.86
Research & Developement to Revenue
2.18
Stock Based Compensation to Revenue
0.77
Gross Profit Margin
0.91
Operating Profit Margin
-2.61
Pretax Profit Margin
-2.3
Net Profit Margin
-2.31

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.12
Free CashFlow per Share
-0.12
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.05
Capex to Depreciation
0.48
Return on Invested Capital
-0.36
Return on Tangible Assets
-0.53
Days Sales Outstanding
13.87
Days Payables Outstanding
823.06
Days of Inventory on Hand
0
Receivables Turnover
26.32
Payables Turnover
0.44
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,20
Book Value per Share
0,35
Tangible Book Value per Share
0.05
Shareholders Equity per Share
0.36
Interest Debt per Share
0.02
Debt to Equity
0.04
Debt to Assets
0.03
Net Debt to EBITDA
1.07
Current Ratio
2.64
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
86929000
Working Capital
0,03 Bil.
Intangibles to Total Assets
0.56
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Lineage Cell Therapeutics, Inc. Dividends
Year Dividends Growth
2003 0

Lineage Cell Therapeutics, Inc. Profile

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

CEO
Mr. Brian M. Culley M.A., M.B.
Employee
68
Address
2173 Salk Avenue
Carlsbad, 92008

Lineage Cell Therapeutics, Inc. Executives & BODs

Lineage Cell Therapeutics, Inc. Executives & BODs
# Name Age
1 Ms. Alexandra Hernandez
Senior Director of Finance & Controller
70
2 Ms. Jill Ann Howe
Chief Financial Officer & Principal Financial and Accounting Officer
70
3 Mr. William Annett MBA
President & Chief Executive Officer of OncoCyte Corporation
70
4 Dr. Harold D. Waitz
Vice President of Regulatory Affairs & Quality Control
70
5 Mr. Brian M. Culley M.A., M.B.A.
Chief Executive Officer, President & Director
70
6 Mr. George A. Samuel III, J.D.
General Counsel & Company Secretary
70
7 Ms. Ioana C. Hone
Director of Investor Relations
70
8 Ms. Brandi L. Roberts CPA, M.B.A.
Consultant
70
9 Dr. Rami Skaliter Ph.D.
Chief Executive Officer of Cell Cure Neurosciences
70
10 Dr. Charlotte Hubbert Ph.D.
Vice President of Corporate Development
70

Lineage Cell Therapeutics, Inc. Competitors